Literature DB >> 10532253

The role of SERMs in the management of postmenopausal osteoporosis.

J Compston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10532253     DOI： 10.1007/BF03343623

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  48 in total

1.  Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.

Authors:  S A Beresford; N S Weiss; L F Voigt; B McKnight
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

2.  Fluoride: the verdict is in, but the controversy lingers.

Authors:  M Kleerekoper
Journal:  J Bone Miner Res       Date:  1996-05       Impact factor: 6.741

3.  Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.

Authors:  T Storm; G Kollerup; G Thamsborg; H K Genant; O H Sørensen
Journal:  J Rheumatol       Date:  1996-09       Impact factor: 4.666

Review 4.  The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly.

Authors:  J E Compston
Journal:  Clin Endocrinol (Oxf)       Date:  1995-10       Impact factor: 3.478

5.  Estrogen therapy arrests bone loss in elderly women.

Authors:  M E Quigley; P L Martin; A M Burnier; P Brooks
Journal:  Am J Obstet Gynecol       Date:  1987-06       Impact factor: 8.661

6.  Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.

Authors:  C Christiansen; M S Christensen; P McNair; C Hagen; K E Stocklund; I Transbøl
Journal:  Eur J Clin Invest       Date:  1980-08       Impact factor: 4.686

7.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

8.  Postmenopausal hormone use and risk of large-bowel cancer.

Authors:  P A Newcomb; B E Storer
Journal:  J Natl Cancer Inst       Date:  1995-07-19       Impact factor: 13.506

9.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Authors:  J A Kanis; O Johnell; B Gullberg; E Allander; G Dilşen; C Gennari; A A Lopes Vaz; G P Lyritis; G Mazzuoli; L Miravet
Journal:  BMJ       Date:  1992-11-07

Review 10.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.